Symbiotec Pharmalab Ltd, a vertically integrated API manufacturer with global leadership in corticosteroid and steroidal-hormone active pharmaceutical ingredients, has set its mainboard IPO price band at ₹938–₹988 per share. This IPO will be offered on both BSE and NSE, with a lot size of 15 shares, bringing the minimum retail investment to ₹14,820.
The issue is scheduled to open for subscription on 24 August 2026 and close on 27 August 2026. Investors looking to participate in this IPO should note these dates carefully to plan their application within the window.
Symbiotec’s positioning as a science-driven biopharmaceutical company adds meaningful industry context — it operates across platforms such as organic chemistry, biotechnology, and complex injectables, and holds a commanding volume market share in key steroid APIs globally.([symbiotec.com](https://www.symbiotec.com/about?utm_source=openai))
| Price Band | ₹938–₹988 |
| Lot Size | 15 shares |
| Minimum Investment (Retail) | ₹14,820 |
| Issue Opens | 24 Aug 2026 |
| Issue Closes | 27 Aug 2026 |
| Exchange | BSE, NSE |
Track live GMP and subscription numbers as the issue approaches on the Symbiotec Pharmalab Ltd IPO page.
Price bands and dates are as announced and may be revised by the company or exchange before the issue opens.